Effects of oral calcitriol on bone mineral density in patients with end-stage renal failure

摘要: Evolution of bone mineral density (BMD) at various skeletal sites and the influence calcitriol on BMD are still poorly documented in patients with terminal renal failure. Using dual photon absorptiometry, we investigated changes levels lumbar spine, femoral neck midfemoral shaft 21 end-stage failure (ESRF) treated (mean dosage +/- SEM: 0.21 0.02 microgram/day) compared them to 25 ESRF but not (control group) over a period 20.3 1.5 17.2 1.2 months, respectively. Lumbar spine increased by 7.7 3.2%/year group decreased 2.5 1.3%/year control (P < 0.005). Femoral more than (+ 6.7 2.3 vs. + 1.4 2.0%/year; P 0.05) remained stable. PTH 92 121 1033 254 pmol/year 0.01) controls, Osteocalcin were -2.7 3.7 +20.1 11.7 micrograms/liter per year same groups. These results indicate that low doses oral associated an increase shaft, stabilization serum osteocalcin concentrations.